KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Research & Development (2017 - 2025)

Twist Bioscience (TWST) has disclosed Research & Development for 6 consecutive years, with $23.7 million as the latest value for Q3 2023.

  • On a quarterly basis, Research & Development fell 19.79% to $23.7 million in Q3 2023 year-over-year; TTM through Sep 2023 was $106.9 million, a 11.15% decrease, with the full-year FY2025 number at $80.3 million, down 11.63% from a year prior.
  • Research & Development was $23.7 million for Q3 2023 at Twist Bioscience, down from $24.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $36.8 million in Q2 2022 to a low of $8.9 million in Q1 2019.
  • A 5-year average of $19.4 million and a median of $19.4 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 97.78% in 2022, then crashed 33.42% in 2023.
  • Twist Bioscience's Research & Development stood at $10.3 million in 2019, then soared by 35.96% to $14.0 million in 2020, then soared by 61.64% to $22.6 million in 2021, then soared by 38.06% to $31.2 million in 2022, then dropped by 23.99% to $23.7 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Research & Development are $23.7 million (Q3 2023), $24.5 million (Q2 2023), and $27.4 million (Q1 2023).